vTv Therapeutics Inc. - ערך חשבונאי למניה VTVT

The lack of revenue and previous research pauses are already priced into vTv Therapeutics Inc. (VTVT) quotes. Future inflows are based on the commercialization of type 1 diabetes therapy and psoriasis treatment. Fluctuations in the book value per share confirm the net asset trend, where the latest mark stands at 19.91. Prospects for a market breakthrough solidify the status of TTP399 as an innovative oral agent supported by the FDA and G42 Healthcare.

vTv Therapeutics Inc. develops highly scalable diabetes therapies, with its primary assets concentrated in intellectual property. The trend in net book value per share reflects the residual capital value after deducting liabilities, allowing investors to assess the actual asset backing of the security and the risk of asset impairment between reporting periods through the analysis of this chart.